GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000164932 | Thyroid | ATC | osteoblast differentiation | 122/6293 | 229/18723 | 6.04e-10 | 1.60e-08 | 122 |
GO:003133035 | Thyroid | ATC | negative regulation of cellular catabolic process | 136/6293 | 262/18723 | 6.47e-10 | 1.71e-08 | 136 |
GO:000188927 | Thyroid | ATC | liver development | 85/6293 | 147/18723 | 1.37e-09 | 3.43e-08 | 85 |
GO:000989529 | Thyroid | ATC | negative regulation of catabolic process | 159/6293 | 320/18723 | 1.61e-09 | 3.99e-08 | 159 |
GO:006100827 | Thyroid | ATC | hepaticobiliary system development | 86/6293 | 150/18723 | 1.96e-09 | 4.78e-08 | 86 |
GO:003461433 | Thyroid | ATC | cellular response to reactive oxygen species | 87/6293 | 155/18723 | 6.54e-09 | 1.43e-07 | 87 |
GO:0051054110 | Thyroid | ATC | positive regulation of DNA metabolic process | 107/6293 | 201/18723 | 7.10e-09 | 1.54e-07 | 107 |
GO:0010821112 | Thyroid | ATC | regulation of mitochondrion organization | 82/6293 | 144/18723 | 7.15e-09 | 1.54e-07 | 82 |
GO:000183722 | Thyroid | ATC | epithelial to mesenchymal transition | 87/6293 | 157/18723 | 1.50e-08 | 3.06e-07 | 87 |
GO:001810519 | Thyroid | ATC | peptidyl-serine phosphorylation | 153/6293 | 315/18723 | 2.28e-08 | 4.42e-07 | 153 |
GO:001820917 | Thyroid | ATC | peptidyl-serine modification | 161/6293 | 338/18723 | 5.23e-08 | 9.44e-07 | 161 |
GO:200027825 | Thyroid | ATC | regulation of DNA biosynthetic process | 62/6293 | 106/18723 | 1.26e-07 | 2.09e-06 | 62 |
GO:007030122 | Thyroid | ATC | cellular response to hydrogen peroxide | 58/6293 | 98/18723 | 1.81e-07 | 2.86e-06 | 58 |
GO:0008625111 | Thyroid | ATC | extrinsic apoptotic signaling pathway via death domain receptors | 50/6293 | 82/18723 | 3.47e-07 | 5.13e-06 | 50 |
GO:004876221 | Thyroid | ATC | mesenchymal cell differentiation | 116/6293 | 236/18723 | 5.08e-07 | 7.30e-06 | 116 |
GO:003109826 | Thyroid | ATC | stress-activated protein kinase signaling cascade | 120/6293 | 247/18723 | 7.06e-07 | 9.46e-06 | 120 |
GO:007189723 | Thyroid | ATC | DNA biosynthetic process | 91/6293 | 180/18723 | 1.84e-06 | 2.24e-05 | 91 |
GO:006048521 | Thyroid | ATC | mesenchyme development | 136/6293 | 291/18723 | 2.04e-06 | 2.43e-05 | 136 |
GO:005140326 | Thyroid | ATC | stress-activated MAPK cascade | 115/6293 | 239/18723 | 2.17e-06 | 2.58e-05 | 115 |
GO:005196014 | Thyroid | ATC | regulation of nervous system development | 195/6293 | 443/18723 | 2.62e-06 | 3.06e-05 | 195 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HGF | SNV | Missense_Mutation | novel | c.1535G>T | p.Arg512Ile | p.R512I | P14210 | protein_coding | deleterious(0.02) | benign(0.054) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | | c.1748N>C | p.Lys583Thr | p.K583T | P14210 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | | c.377N>C | p.Arg126Thr | p.R126T | P14210 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD |
HGF | SNV | Missense_Mutation | | c.248C>G | p.Thr83Ser | p.T83S | P14210 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-BH-A0BF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | | c.1913N>A | p.Gly638Glu | p.G638E | P14210 | protein_coding | deleterious(0.03) | probably_damaging(0.979) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
HGF | SNV | Missense_Mutation | rs778704152 | c.1675N>A | p.Glu559Lys | p.E559K | P14210 | protein_coding | tolerated(0.44) | probably_damaging(0.992) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HGF | SNV | Missense_Mutation | rs777593933 | c.589C>T | p.Arg197Cys | p.R197C | P14210 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HGF | SNV | Missense_Mutation | | c.686N>C | p.Gly229Ala | p.G229A | P14210 | protein_coding | deleterious(0) | possibly_damaging(0.672) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
HGF | SNV | Missense_Mutation | | c.343N>C | p.Glu115Gln | p.E115Q | P14210 | protein_coding | tolerated(0.28) | benign(0.352) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
HGF | SNV | Missense_Mutation | | c.331G>A | p.Glu111Lys | p.E111K | P14210 | protein_coding | tolerated(0.86) | benign(0) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | STI571 | IMATINIB MESYLATE | 11439348 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | THALIDOMIDE | THALIDOMIDE | 15939924 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | ASPIRIN | ASPIRIN | 11981761 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | VM-202 | | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | Ficlatuzumab | FICLATUZUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | PROTEOLYTIC ENZYMES | | 9502079 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | antibody | RILOTUMUMAB | RILOTUMUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | RESVERATROL | RESVERATROL | 15672869 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | TAK-701 | | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | FICLATUZUMAB | FICLATUZUMAB | |